This page features ACC's full coverage of the latest science from Transcatheter Cardiovascular Therapeutics (TCT) 2026, taking place Oct. 31 to Nov. 3, 2026 in San Diego, CA.

Roxana Mehran, MD, FACC, today assumed the role of president of the American College of Cardiology. Mehran will serve a one-year term at the helm of the almost 60,000-member global cardiovascular ...

Silent atherosclerosis is detectable using imaging in early adulthood, with age- and sex-associated increases in prevalence across arterial territories and significant increases in plaque volume, ...

A new clinical guideline released by the ACC and the American Heart Association (AHA) includes new evidence and updated recommendations for managing patients with an ...

Among community-dwelling older adults, treatment with atorvastatin demonstrated a 30% relative reduction in major cardiovascular events over roughly six years compared with placebo but did not result ...

In IDEAL-AF, simultaneously published in JAMA, adjunctive low-voltage zone ablation following pulmonary vein isolation improved rhythm outcomes and health-related quality of life without increasing ...

About 50% of U.S. adults will develop high BP during their lifetime. High BP is the most prevalent and modifiable risk factor for cardiovascular disease and all-cause mortality. The overarching BP ...

Inflammation plays a central role in the pathogenesis of atherosclerosis and cardiovascular disease. 1 Atherosclerosis in particular is an inflammatory process that involves endothelial dysfunction, ...

In patients with atrial fibrillation (AFib) at intermediate risk for stroke, DOAC therapy resulted in a lower risk of stroke, systemic embolism, major bleeding or death from cardiovascular causes at ...

Interventional science was the focus of a Hot Line Session at ESC Congress 2026, with studies shedding light on milvexian with antiplatelet therapy following an acute coronary event; aspirin omission ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

In TAVI PCI, which was simultaneously published in NEJM, a strategy of TAVI before PCI was noninferior to a PCI-first strategy in patients with severe aortic stenosis and concomitant coronary artery ...